PMV Pharmaceuticals, Inc. — Director's Dealing 2025

Mar 5, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2025-03-03

Reporting Person: Mack David Henry (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-03	Employee Stock Option (right to buy)	$1.32	A	800000	Acquired	2035-03-03	Common Stock (800000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	579016	Direct
Common Stock	165307	Indirect
Common Stock	147915	Indirect
Common Stock	56978	Indirect

Footnotes

F1: Includes 27,097 shares acquired under the Issuer's Employee Stock Purchase Plan as follows: 2,777 shares acquired on May 20, 2021; 2,560 shares acquired on November 21, 2022; 10,023 shares acquired on November 20, 2023 and 11,737 shares acquired on November 20, 2024.

F2: The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F3: The shares are held of record by the Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F4: The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

F5: Shares subject to the option vest in 48 equal monthly installments beginning on April 3, 2025.